Hubei Biocause Pharmaceutical Co., Ltd. operates in the Industrial organic chemicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hubei Biocause Pharmaceutical Co., Ltd. with three other
companies in this sector in China:
Shanghai Huayi Group Corp Ltd
(2017
sales of 43.73 billion Chinese Renmimbi [US$6.39 billion]
of which 51%
was Chemical Services),
China Petroleum Engineering Corp
(55.36 billion Chinese Renmimbi [US$8.09 billion]
of which 40%
was Oil and Gas Field Surface Engineering), and
Zibo Qixiang Tengda Chemical Company Limited
(22.23 billion Chinese Renmimbi [US$3.25 billion]
of which 57%
was Supply Chain).
Sales Analysis.
Sales increased substantially in 2017:
Hubei Biocause Pharmaceutical Co., Ltd. reported sales of 53.41 billion Chinese Renmimbi (US$7.80 billion)
for the
year ending
December of 2017.
This
represents
an
increase of 214.3%
versus 2016, when the company's sales were 16.99 billion Chinese Renmimbi.
Sales of Insurance saw an increase
that was more than double the company's growth rate: sales were up
496.1% in 2017, from
8.87 billion Chinese Renmimbi to 52.89 billion Chinese Renmimbi.
Not all segments of Hubei Biocause Pharmaceutical Co., Ltd. experienced an increase in sales in 2017:
sales of Chemical Manufacturing fell 58.1% to 149.13 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
Hubei Biocause Pharmaceutical Co., Ltd. also experienced decreases in sales in
Pharmaceutical Manufacturing (down 23.0% to 370.51 million Chinese Renmimbi)
.